124 related articles for article (PubMed ID: 32894394)
1. TERT promotor region rearrangements analyzed in high-risk neuroblastomas by FISH method and whole genome sequencing.
Kawashima M; Ueda Y; Kurihara S; Hiyama E
Int J Clin Oncol; 2020 Dec; 25(12):2166-2174. PubMed ID: 32894394
[TBL] [Abstract][Full Text] [Related]
2. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
4. Translational practice of fluorescence in situ hybridisation to identify neuroblastic tumours with TERT rearrangements.
Yu Y; Zhang M; Yao X; Guan X; Jia C; Chu P; Zhang R; Yang Y; Jin Y; Wang H; Ni X; He L; Guo Y
J Pathol Clin Res; 2023 Nov; 9(6):475-487. PubMed ID: 37608330
[TBL] [Abstract][Full Text] [Related]
5. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
[TBL] [Abstract][Full Text] [Related]
6. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.
Valentijn LJ; Koster J; Zwijnenburg DA; Hasselt NE; van Sluis P; Volckmann R; van Noesel MM; George RE; Tytgat GA; Molenaar JJ; Versteeg R
Nat Genet; 2015 Dec; 47(12):1411-4. PubMed ID: 26523776
[TBL] [Abstract][Full Text] [Related]
7. Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
Roderwieser A; Sand F; Walter E; Fischer J; Gecht J; Bartenhagen C; Ackermann S; Otte F; Welte A; Kahlert Y; Lieberz D; Hertwig F; Reinhardt HC; Simon T; Peifer M; Ortmann M; Büttner R; Hero B; O'Sullivan RJ; Berthold F; Fischer M
JCO Precis Oncol; 2019 Dec; 3():1-20. PubMed ID: 35100718
[TBL] [Abstract][Full Text] [Related]
8. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
[TBL] [Abstract][Full Text] [Related]
9. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
[TBL] [Abstract][Full Text] [Related]
10. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
[TBL] [Abstract][Full Text] [Related]
11. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
[TBL] [Abstract][Full Text] [Related]
14. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
Onitake Y; Hiyama E; Kamei N; Yamaoka H; Sueda T; Hiyama K
J Pediatr Surg; 2009 Dec; 44(12):2258-66. PubMed ID: 20006006
[TBL] [Abstract][Full Text] [Related]
15. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
16. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
18. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.
Duan XF; Zhao Q
J Pediatr Hematol Oncol; 2018 Jan; 40(1):1-6. PubMed ID: 28452859
[TBL] [Abstract][Full Text] [Related]
19. Rearrangement in the coding region of the MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN amplification.
Chen B; Jhanwar SC; Ladanyi M
Diagn Mol Pathol; 2001 Jun; 10(2):100-4. PubMed ID: 11385318
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
